TY - JOUR
T1 - XAGE-1 mRNA expression in prostate cancer and antibody response in patients
AU - Koizumi, Fumihito
AU - Noguchi, Yuji
AU - Saika, Takashi
AU - Nakagawa, Kazuhiko
AU - Sato, Shuichiro
AU - Eldib, Ali Mohamed Ali
AU - Nasu, Yasutomo
AU - Kumon, Hiromi
AU - Nakayama, Eiichi
PY - 2005
Y1 - 2005
N2 - To evaluate the feasibility of cancer vaccine targeting XAGE-1, we investigated the expression of 4 XAGE-1 transcript variants and the humoral immune response to XAGE-1 in prostate cancer patients. XAGE-1a, b, c, d mRNA expression was analyzed in 54 prostate cancer specimens and 8 specimens of benign prostate hypertrophy (BPH) by reverse transcription-polymerase chain reaction (RT-PCR). The humoral response to XAGE-1 was investigated in sera obtained from 278 patients with prostate cancer and 40 healthy volunteers by enzyme-linked immunosorbent assay (ELISA) using recombinant protein. XAGE-1b mRNA expression was observed in 14 of 54 (26%) prostate cancer specimens, while XAGE-1a, c, and d mRNA expressions were observed in 1,1, and 3, respectively. None of the 4 XAGE-1 transcript variants was observed in the 8 BPH specimens. Antibody against XAGE-1 was detected in sera from 2 of 129 stage D2 patients, whereas none of sera from 149 patients with localized prostate cancer or lymph node metastasis had detectable XAGE-1 antibody. No reactivity to XAGE-1 was found in sera from the 40 healthy individuals.
AB - To evaluate the feasibility of cancer vaccine targeting XAGE-1, we investigated the expression of 4 XAGE-1 transcript variants and the humoral immune response to XAGE-1 in prostate cancer patients. XAGE-1a, b, c, d mRNA expression was analyzed in 54 prostate cancer specimens and 8 specimens of benign prostate hypertrophy (BPH) by reverse transcription-polymerase chain reaction (RT-PCR). The humoral response to XAGE-1 was investigated in sera obtained from 278 patients with prostate cancer and 40 healthy volunteers by enzyme-linked immunosorbent assay (ELISA) using recombinant protein. XAGE-1b mRNA expression was observed in 14 of 54 (26%) prostate cancer specimens, while XAGE-1a, c, and d mRNA expressions were observed in 1,1, and 3, respectively. None of the 4 XAGE-1 transcript variants was observed in the 8 BPH specimens. Antibody against XAGE-1 was detected in sera from 2 of 129 stage D2 patients, whereas none of sera from 149 patients with localized prostate cancer or lymph node metastasis had detectable XAGE-1 antibody. No reactivity to XAGE-1 was found in sera from the 40 healthy individuals.
KW - Cancer/testis antigen
KW - Prostate cancer
KW - XAGE-1
UR - http://www.scopus.com/inward/record.url?scp=20444366620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20444366620&partnerID=8YFLogxK
U2 - 10.1111/j.1348-0421.2005.tb03751.x
DO - 10.1111/j.1348-0421.2005.tb03751.x
M3 - Article
C2 - 15905609
AN - SCOPUS:20444366620
VL - 49
SP - 471
EP - 476
JO - Microbiology and Immunology
JF - Microbiology and Immunology
SN - 0385-5600
IS - 5
ER -
